Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long non-coding RNAs (lncRNAs) are aberrantly expressed in various cancers.
Fer-1-like protein 4
(
FER1L4
), one of lncRNAs, plays a role as tumor suppressor in various human cancers and can be regulated by microRNA. However, the role and function of
FER1L4
in human
hepatocellular carcinoma
(
HCC
) remains unknown. The aim of the present study was to annotate the role of
FER1L4
and its clinical value in
HCC
. In the present study, we found that
FER1L4
was lowly expressed in
HCC
tissue specimens as well as in malignant
HCC
cell lines, while the situation is opposite in miR-106a-5p. We found that down-regulated
FER1L4
increased the expression of miR-106a-5p significantly and there was a reciprocal repression between
FER1L4
and miR-106a-5p. Moreover, we identified
FER1L4
as a target of miR-106a-5p by using dual-luciferase reporter assay. Knockdown of
FER1L4
promoted the malignancy of
HCC
cells, including proliferation, migration, and invasion, and inhibited cell apoptosis. We also found that
FER1L4
functions as a tumor suppressor in vivo. Together, these results suggest that
FER1L4
could exert a tumor suppressive impact on
HCC
, which at least, in part, through suppressing miR-106a-5p expression.
FER1L4
, as well as miR-106a-5p, can predict the clinical prognosis of
HCC
alone or combined, which may be a novel therapeutic target for treating
HCC
.
...
PMID:Long non-coding RNA Fer-1-like protein 4 acts as a tumor suppressor via miR-106a-5p and predicts good prognosis in hepatocellular carcinoma. 2875 56
Novel long non-coding RNA
Fer-1-like protein 4
(
FER1L4
) has been identified as a tumor suppressor in endometrial carcinoma, ovarian cancer,
hepatocellular carcinoma
, esophageal squamous cell carcinoma. However, the function of
FER1L4
in osteosarcoma has not been clear. The aim of the research was to explore the effects of
FER1L4
in osteosarcoma. Results showed that
FER1L4
was observed to be lowly expressed in osteosarcoma cell lines (US-O2, MG-63 and SaOS-2 cells), especially MG63 cells. Besides, overexpression of
FER1L4
remarkably repressed the proliferation, migration and invasion of MG63 cells.
FER1L4
-induced apoptotic cell death leaded to the activation of caspase-3 and Bax/Bcl2. Moreover, epithelial-mesenchymal transition (EMT) was tremendously suppressed by increased
FER1L4
, evidences were the increased E-cadherin and reduced vimentin and fibronectin. Blocking
FER1L4
expression by sh-
FER1L4
treatment increased the expression of SOX9, CD44, ALDH1, Nanog and Oct4, indicating that
FER1L4
could effectively decrease cell stemness in osteosarcoma. Furthermore, the protein levels of p-AKT and p-PI3K were remarkably suppressed when
FER1L4
was knocked down. In conclusion, the study indicated that
FER1L4
acted as a tumor suppressor in osteosarcoma via activating PI3K/AKT pathway may be a new prognostic biomarker and potential therapeutic target for osteosarcoma intervention.
...
PMID:Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells. 3100 Mar 82